Last reviewed · How we verify

Exonhit — Portfolio Competitive Intelligence Brief

Exonhit pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. IRCCS San Raffaele · 1 shared drug class
  2. National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Exonhit:

Cite this brief

Drug Landscape (2026). Exonhit — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/exonhit. Accessed 2026-05-13.

Related